<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428035</url>
  </required_header>
  <id_info>
    <org_study_id>V01-01</org_study_id>
    <nct_id>NCT03428035</nct_id>
  </id_info>
  <brief_title>The Impact of a Neutral Formulated and Designed Package Insert on Nocebo-effect.</brief_title>
  <acronym>NEUPANO</acronym>
  <official_title>Neutral Formulated and Designed Package Insert or Only Verbal Information Compared to Package Insert According EU-directive: a Pilot Randomised Controlled Trial to Analyse the Influence on the Nocebo Effect and Non-adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Witten/Herdecke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Witten/Herdecke</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background The nocebo effect describes the association between the expectation of negative
      effects, (e.g. side effects) and the actual occurrence of negative effects. Studies have
      shown that the nocebo effect can be influenced by (risk) communication. Till today there is
      no study that compares different types of information on adverse events regarding the
      strength of the nocebo effect.

      Aim The aim of this pilot randomized controlled trial is to analyse the influence of
      different communication types on the frequency and intensity of adverse events and adherence.
      To increase the relevance and applicability of the results the study intervention builds up
      on package inserts because these are the most widespread form of information on side effects.

      Methods Patients It is planned to include 60 patients in the study.

      Intervention

        -  Modified package insert: simplified and focused on neutral risk perception. The
           representations and formulations are based on the findings from research on
           evidence-based patient information and risk communication. The package insert contains
           the same information as the statutory package insert to ensure that it complies with the
           legal requirements.

        -  Verbal information about side effects: The patient is informed verbally about side
           effects and does not receive any package insert.

      Control Package insert according to EU (European Union) Directive 2001/83 / EC (European
      Commission) (usual package insert).

      Outcomes

        -  Number of patient reported adverse events (primary outcome).

        -  Adherence (correct initiation of therapy, correct intake amount, premature
           discontinuation of therapy).

        -  Resource use (e.g. provider contacts).

      Type of study Monocentric, outcome assessor, three-arm, randomised controlled pilot trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient reported adverse events</measure>
    <time_frame>6-9 days after surgery</time_frame>
    <description>Any reported adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>6-9 days after surgery</time_frame>
    <description>Correct initiation of therapy, correct intake amount, premature discontinuation of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource use</measure>
    <time_frame>6-9 days after surgery</time_frame>
    <description>e.g. provider contacts</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Orthopedic Surgery</condition>
  <arm_group>
    <arm_group_label>Modified Package Insert</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verbal Information</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patient is informed verbally about side effects and does not receive any package insert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Package insert according to EU Directive 2001/83 / EC (usual package insert)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Package Insert</intervention_name>
    <description>Modified package insert of Ibuprofen given postprocedural as pain medication</description>
    <arm_group_label>Modified Package Insert</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Patient Education</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective orthopaedic surgery

          -  planned intake of ibuprofen 600 mg to treat postoperative pain

          -  postoperative pain medication other than Ibuprofen 600 (Opioids, Opiate, Paracetamol)
             no longer than 1-2 days postoperative (until discharge)

          -  at least 18 years

          -  able to speak German

          -  no cognitive deficits

          -  written informed consent

        Exclusion Criteria:

          -  serious comorbidity

          -  pain medication prior to surgery

          -  other medication with similar side effects

          -  polytrauma

          -  planned inpatient rehabilitation &gt; one week after hospital discharge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Mathes, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Witten/Herdecke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Prediger</last_name>
    <phone>+4922198957</phone>
    <phone_ext>44</phone_ext>
    <email>Barbara.Prediger@uni-wh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tim Mathes, Dr.</last_name>
    <phone>+4922198957</phone>
    <phone_ext>43</phone_ext>
    <email>Tim.Mathes@uni-wh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic for orthopedics, trauma surgery and sports traumatology, hospital Cologne Merheim</name>
      <address>
        <city>Cologne</city>
        <state>North-Rhine-Westfalia</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Prediger</last_name>
      <phone>+492219895744</phone>
      <email>barbara.prediger@uni-wh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Witten/Herdecke</investigator_affiliation>
    <investigator_full_name>Tim Mathes</investigator_full_name>
    <investigator_title>Dr. Tim Mathes</investigator_title>
  </responsible_party>
  <keyword>Randomized controlled trial</keyword>
  <keyword>package insert</keyword>
  <keyword>nocebo</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol and clinical study report will be shared as supplement with the journal publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

